Arena Pharmaceuticals — Investor Presentation (February 2018)
27 slides from Arena Pharmaceuticals's investor presentation, Feb 15, 2018

Slide 1: Corporate Presentation February 2018
February 2018 Non-Confidential Corporate Presentation Exhibit 99.1

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-class), safety, effic

Slide 3: Executive Summary: Catalyst Rich 2018
Executive Summary Catalyst Rich 2018 - Multiple Potentially First / Best-in-Class Programs Q1 Q2 2H Ralinepag Ph 3 program plan Etrasimod UC Ph 2 data APD371 Crohn’s pain Ph 2 data Ralinepag Ph 3 initiation Etrasimod new indications initiation Cardiopulmonary pipeline expansion Etrasimod in PBC & PG

Slide 4: Focus on Pipeline: Differentiated Assets with High-Value Potential
Program Therapeutic Area/Indication PC Ph 1 Ph 2 Ph 3 Timing Ralinepag Potent IP Receptor Agonist Pulmonary Arterial Hypertension (PAH) Ph 3 Preparations Etrasimod Optimized Activity S1P Receptor Modulator Ulcerative Colitis (UC) Ph 2 Data Q1 2018 Primary Biliary Cholangitis (PBC) Initiated Ph 2 Pyo

Slide 5: Ralinepag
A Next-Generation, Oral, Selective Prostacyclin Receptor (IP) Agonist for the Treatment of Pulmonary Arterial Hypertension Ralinepag

Slide 6: Phase 3 Ready Ralinepag: Potential to Redefine Treatment Paradigm in PAH
Phase 3 Ready Ralinepag 1996 Barst - Unremitting 24 h coverage with IV prostacyclin improves survival1 Difficulty of administration and maintenance limits IV to last line Unmet Need in $6.7B2 PAH Market 6.5-10x improved potency compared to selexipag Long half-life (>24 h), IV-like unremitting recept

Slide 7: Ralinepag Significantly Improved Pulmonary Vascular Resistance
Ralinepag Significantly Improved Pulmonary Vascular Resistance (PVR); ITT Population Primary Endpoint: Change in PVR Geometric Mean Ratio (GMR) [Expressed as Percent Change] Treatment Effect Comparison -25.8% over placebo (p=0.02) Mean absolute change from baseline: placebo 25.5, ralinepag -175.7 dy

Slide 8: Safety and Tolerability
The overall safety and tolerability profile consistent with the known profile of the prostacyclin therapy class Adverse events that occurred most frequently on ralinepag were similar to the on-target effects expected for prostacyclin therapies: Headache, nausea, diarrhea, jaw pain, flushing Events w

Slide 9: Ralinepag Phase 3 Clinical Program: Three Studies Initiating in Parallel
Ralinepag Phase 3 Clinical Program Three Studies Initiating in Parallel Ph 3 Studies 1 – Exercise Capacity Registrational 2 - Comparator / Head-to-Head Supportive 3 – Clinical Events Label Expansion Endpoints 1º-CPET 2º -6MWD Hemodynamics Time to clinical events Incident or Prevalent Incident Confid

Slide 10: CPET Provides a Multi-Dimensional Assessment of Exercise Capacity
CPET Provides a Multi-Dimensional Assessment of Exercise Capacity More Accurate Measurement of Exercise Capacity Peak VO2 (maximum oxygen consumed during exercise) VE/VCO2 (minute ventilation / carbon dioxide production) Key CPET Measures Highly sensitive measure of impact - both diagnostic and prog

Slide 11: VE/VCO2 Slope and Other CPET Variables in Guideline-Based PAH Management
6MWD <165m 6MWD 165-440m Intermediate Risk (5-10% estimated 1y mortality) 6MWD >440m Adapted from Galiè, N et al European Heart Journal (2016) 37, 67–119 doi:10.1093/eurheartj/ehv317 VE/VCO2 Slope and Other CPET Variables are Integral Components of Guideline-Based PAH Management High Risk (>10% esti

Slide 12: CPET Superior Measurement for Exercise Capacity
CPET Superior Measurement for Exercise Capacity Less subjective Lower variability Minimizes confounding factors Course design BMI Co-morbid conditions i.e. scleroderma Weather Greater sensitivity to detect treatment effect 1) Arena R et al. Circulation. 2007 May 8;115(18):2410-7. doi: 10.1161/CIRCUL

Slide 13: Etrasimod
Oral, Next Generation, S1P Receptor Modulator Optimized Activity Being Evaluated for Multiple Immune-Inflammatory Diseases Etrasimod

Slide 14: Promise of Etrasimod
Promise of Etrasimod Unmet need for safe and effective oral agents addressing a broad range of immune-inflammatory diseases S1P modulation offers the promise of effective treatment in 80+ conditions First-generation pan-S1P modulators (fingolimod - Gilenya®) risk-benefit profile limits utility Secon

Slide 15: Etrasimod's Highly Selective S1P Modulation May Avoid Off-Target Activity
Associated with Cardiac, Pulmonary & Possible Tumor-related Risks Decreased Inflammation & Improvement in Immune-Inflammatory Disorders Positive Outcome Negative Outcome Dendritic Cells Reduces Immune Cell Migration, Differentiation & Proliferation Increased Vasoconstriction, Fibrosis & Proliferatio

Slide 16: Etrasimod Does Not Induce S1PR2 Internalization
In Contrast with Other S1P Modulators, Etrasimod Does Not Induce S1PR2 Internalization (In Vitro Studies) S1P Agonists Induce S1PR1 Internalization (S1PR1 Internalization Assay) Etrasimod Does Not Induce S1PR2 Internalization (S1PR2 Internalization Assay) -12 -11 -10 -9 -8 -7 -6 -5 log [Agonist] (M)

Slide 17: Optimal Selectivity: Opportunity to be Best-in-Class
Optimal Selectivity Opportunity to be best-in-class therapy More Selective S1P2 internalization Ozanimod2 (Celgene) Nonselective Promiscuous binding can lead to off-target effects4 & more AEs5 a Elevated LFTs ≥ 3 × upper limit of normal. *Note – Data Collected from Separate Studies – Cannot be Direc

Slide 18: Etrasimod Has a Quick Onset of Action
Etrasimod Has a Quick Onset of Action – Phase 1 Data *After dose escalation of ozanimod (0.3 mg/d on days 1–3; 0.6 mg/d on days 4 and 5; 1 mg/d on days 6 and 7; and 3 mg/d on days 8–10. Data truncated at day 11 (ozanimod) and 15 (etrasimod) to show on-treatment onset effects Sources: 1-Tran JQ et al

Slide 19: Etrasimod Has a Quick Offset of Action
Etrasimod Has a Quick Offset of Action – Phase 1 Data Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2- ADP334 P1 Data on File; Ozanimod1 Etrasimod2 Ozanimod, 1 mg (Fixed dose) Placebo Etrasimod, 2 mg (Fixed Dose) Placebo Treatment days Within 1 week after last dose of etrasimod, lymph

Slide 20: Etrasimod First Dose Has Little Impact on Heart Rate
Etrasimod First Dose Has Little Impact on Heart Rate Over 24 Hrs – Phase 1 Data Ozanimod, 1 mg Single Dose (n=18) Ozanimod, 2 mg Single Dose (n=12) Placebo (n=9) Etrasimod, 2 mg, Single Dose (n=10) Ozanimod1 Etrasimod2 Note – Data Collected from Separate Studies – Cannot be Directly Compared Sources

Slide 21: Etrasimod Phase 2 Trial in UC
Enrolled patients with moderate to severe UC (3-component Mayo score of 4-9 that includes endoscopic sub score >2, rectal bleeding score >1) Efficacy endpoints include improvement in Mayo Clinical Score (3-component, total), response, remission, mucosal healing versus placebo and dose response Safet

Slide 22: Etrasimod Clinical Program: Expanding Indications
Etrasimod Clinical Program Expanding Indications 1. Vavricka, SR et al. ”Extraintestinal Manifestations of Inflammatory Bowel Disease” Inflammatory Bowel Diseases August 2015 2. Taverela VF. ”Review article: skin complications associated with inflammatory bowel disease” Aliment Pharmacol Ther 2004 3

Slide 23: APD371
APD371 Peripherally Restricted, Highly–Selective, Full Agonist to Cannabinoid 2 Receptor (CB2) Being Evaluated for Treatment of Pain Associated with Crohn’s Disease

Slide 24: Promise of APD371
Promise of APD371 Opioid epidemic is a public health emergency No drugs developed for the treatment of visceral pain including: Inflammatory bowel disease Interstitial cystitis Pancreatitis Endometriosis Chronic prostatitis 1/8 IBD patients on chronic opioids Unmet Need in Pain Designed to be periph

Slide 25: CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells
CB2 Receptors Are Expressed in the Enteric Nervous System and Immune Cells Within GI Tract CB2 receptors located in target tissue, neurons & local immune cells in GI tract CB2 receptor also expressed on visceral afferent nerves During inflammation, enhanced expression on epithelial cells at the ulce

Slide 26: Executive Summary: Catalyst Rich 2018
Executive Summary Catalyst Rich 2018 - Multiple Potentially First / Best in Class Programs Q1 Q2 2H Ralinepag Ph 3 program plan APD371 Crohn’s pain Ph 2 data Ralinepag Ph 3 initiation Etrasimod new indications initiation Cardiopulmonary pipeline expansion Etrasimod in PBC & PG Next Up – Etrasimod Ph

Slide 27: Thank you
PHARMACEUTICALS Thank you NASDAQ: ARNA
Source: SEC EDGAR · 8-K filed Feb 15, 2018
More decks from Arena Pharmaceuticals Inc
Merger or Acquisition (December 2021)14 slides · Dec 14, 2021
Merger or Acquisition (December 2021)9 slides · Dec 13, 2021
Investor Presentation (January 2021)21 slides · Jan 11, 2021
Investor Presentation (November 2020)35 slides · Nov 18, 2020
Investor Presentation (October 2020)32 slides · Oct 26, 2020
Corporate Update (September 2020)13 slides · Sep 23, 2020